The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
Public ClinicalTrials.gov record NCT01131845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Evaluation of the Pharmacokinetics and Safety of a Single Dose of UT-15C SR (Treprostinil Diethanolamine) in Subjects With Renal Impairment.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a single-center, open-label, single-dose evaluation of 1 mg UT-15C SR pharmacokinetics, safety, and tolerability in subjects with normal, mild, moderate and end stage renal disease (ESRD; on dialysis). Subjects in the ESRD group will receive 2 doses of UT-15C SR, separated by 14 days. One dose will be given 4 hours prior to dialysis, the other dose will be given at the end of dialysis. Pharmacokinetic samples will be taken immediately prior to dosing and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, 30, 36, 42 and 48 hours post dose. Additionally, subjects with ESRD will have a sample taken at 60 hrs post dose.
Study identification
- NCT ID
- NCT01131845
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Aug 31, 2010
- Completion
- Aug 31, 2010
- Last update posted
- May 16, 2012
2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Orlando Clinical Research Center | Orlando | Florida | 32809 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Pulmonary Arterial Hypertension trials
Other public records listing Pulmonary Arterial Hypertension. Sorted by last update posted; newest first. Not a recommendation.
- NCT01712620: Spironolactone for Pulmonary Arterial Hypertension Recruiting
- NCT07781709: UNDERSTANDING THE EFFECTS OF PULMONARY ARTERIAL HYPERPTENSION ON LEAN MUSCLE MASS-SUBSTUDY Not yet recruiting
- NCT07143448: A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults Recruiting
- NCT06992440: Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension Recruiting
- NCT04991454: Xenon MRI Pulm Hypertension Recruiting
- NCT07751120: Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH. Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01131845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2012 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01131845 live on ClinicalTrials.gov.